5 Analysts Have This To Say About Enovis
Portfolio Pulse from Benzinga Insights
Analysts have diverse opinions on Enovis (NYSE:ENOV), with recent ratings ranging from bullish to bearish. Over the last three months, 5 analysts have updated their views, showing a shift towards more bullish sentiments. The average 12-month price target is now $72.2, up from $65.67, indicating a 9.94% increase. Enovis, a medical technology company, has shown positive revenue growth and strong financial health indicators despite a lower market capitalization compared to industry peers.
February 13, 2024 | 12:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Enovis has received diverse analyst ratings, with a shift towards more bullish sentiments in the last three months. The average 12-month price target has increased to $72.2, indicating a potential upside of 9.94%.
The shift towards more bullish analyst ratings and the increase in the average price target suggest a positive outlook for Enovis. The company's strong financial health indicators and positive revenue growth further support this optimistic view. Given these factors, the short-term impact on ENOV's stock price is likely to be positive.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100